Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

In patients with polycythemia vera (PV), an elevated JAK2 p.V617F allele burden is associated with indicators of more severe disease (e.g., leukocytosis, splenomegaly, and increased thrombosis risk); however, correlations between allele burden reductions and clinical benefit in patients with PV have...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Hematol
Main Authors: Vannucchi, Alessandro Maria, Verstovsek, Srdan, Guglielmelli, Paola, Griesshammer, Martin, Burn, Timothy C., Naim, Ahmad, Paranagama, Dilan, Marker, Mahtab, Gadbaw, Brian, Kiladjian, Jean-Jacques
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2017
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5486779/
https://ncbi.nlm.nih.gov/pubmed/28456851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-017-2994-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares